Niagen Bioscience can either commercialise the drug candidate independently or sublicense to a strategic pharmaceutical ...

Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine ...

Investing.com -- Niagen Bioscience Inc (NASDAQ: NAGE) stock rose 2% after the company announced an exclusive worldwide commercial license agreement with Norway’s Haukeland University Hospital to ...

Niagen Bioscience, Inc., the global authority on NAD+ with a focus on the science of healthy aging, today announces that senior management will participate at the Roth 15 th Annual London ...

Niagen Bioscience Inc. has reached a significant milestone as its stock hit a 52-week high of 14.49 USD, with InvestingPro data showing the company maintains a "GREAT" overall financial health ...

The buzzy supplement is beloved by celebrities and starting to show up in skin care. But what can it actually do?

The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full ...

Niagen Bioscience CFO, Ozan Pamir, will attend in-person one-on-one meetings with institutional investors throughout the conference.

Discover why NAGE's Tru Niagen leads the NAD+ market, backed by health trends, growth potential, and a 20%+ stock upside.

Niagen Bioscience Inc. (NASDAQ:NAGE) saw its stock rise 2% after securing an exclusive global commercial license from Norway’s Haukeland University Hospital to develop its nicotinamide riboside ...

Niagen Bioscience Inc. has reached a significant milestone as its stock hit a 52-week high of 14.49 USD, with InvestingPro data showing the company maintains a "GREAT" overall financial health score ...

Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces ...